These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 21422148)
21. A comparative study of contamination in three closed systems for the preparation of hazardous drugs through simulations with fluorescein. González-Haba-Peña E; Manrique-Rodríguez S; Herranz-Alonso AM; Iglesias-Peinado I; Sanjurjo-Sáez M Farm Hosp; 2018 Nov; 42(6):234-238. PubMed ID: 30381043 [TBL] [Abstract][Full Text] [Related]
22. Reduction of Contamination with Antibiotics on Surfaces and in Environmental Air in Three European Hospitals Following Implementation of a Closed-System Drug Transfer Device. Sessink PJM; Nyulasi T; Haraldsson ELM; Rebic B Ann Work Expo Health; 2019 Apr; 63(4):459-467. PubMed ID: 30852616 [TBL] [Abstract][Full Text] [Related]
23. Effectiveness of a Closed-System Transfer Device in Reducing Surface Contamination in a New Antineoplastic Drug-Compounding Unit: A Prospective, Controlled, Parallel Study. Simon N; Vasseur M; Pinturaud M; Soichot M; Richeval C; Humbert L; Lebecque M; Sidikou O; Barthelemy C; Bonnabry P; Allorge D; Décaudin B; Odou P PLoS One; 2016; 11(7):e0159052. PubMed ID: 27391697 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of surface contamination in a hospital hematology--oncology pharmacy. Touzin K; Bussières JF; Langlois E; Lefebvre M J Oncol Pharm Pract; 2009 Mar; 15(1):53-61. PubMed ID: 18772214 [TBL] [Abstract][Full Text] [Related]
25. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Harrison BR; Peters BG; Bing MR Am J Health Syst Pharm; 2006 Sep; 63(18):1736-44. PubMed ID: 16960258 [TBL] [Abstract][Full Text] [Related]
26. Effectiveness of a decontamination procedure in a pharmacy buffer room contaminated by 5 antineoplastic agents. Arpino P; Yeomelakis J; Oommen A Am J Health Syst Pharm; 2020 Dec; 77(24):2081-2088. PubMed ID: 33150407 [TBL] [Abstract][Full Text] [Related]
27. Patterns and characteristics associated with surface contamination of hazardous drugs in hospital pharmacies. Salch SA; Zamboni WC; Zamboni BA; Eckel SF Am J Health Syst Pharm; 2019 Apr; 76(9):591-598. PubMed ID: 31361828 [TBL] [Abstract][Full Text] [Related]
28. Development of a closed drug preparation method for oral anticancer drugs. Wakui N; Ookubo T; Iwasaki Y; Ito R; Saito K; Nakazawa H J Oncol Pharm Pract; 2013 Dec; 19(4):315-20. PubMed ID: 23292970 [TBL] [Abstract][Full Text] [Related]
29. Chemical contamination during the preparation of cytotoxics: validation protocol for operators in hospital pharmacies. Sadeghipour F; Lorenzini KI; Ziewitz C; Dobrinas M; Fleury M; Bonnabry P J Oncol Pharm Pract; 2013 Mar; 19(1):57-64. PubMed ID: 22777996 [TBL] [Abstract][Full Text] [Related]
30. Exposure to antineoplastic drugs in two UK hospital pharmacy units. Mason HJ; Blair S; Sams C; Jones K; Garfitt SJ; Cuschieri MJ; Baxter PJ Ann Occup Hyg; 2005 Oct; 49(7):603-10. PubMed ID: 15964878 [TBL] [Abstract][Full Text] [Related]
31. Identification and reduction of hazardous drug surface contamination through the use of a novel closed-system transfer device coupled with a point-of-care hazardous drug detection system. Brechtelsbauer E Am J Health Syst Pharm; 2023 Mar; 80(7):435-444. PubMed ID: 36370411 [TBL] [Abstract][Full Text] [Related]
32. Aseptic simulation test for cytotoxic drug production in isolators. Savry A; Correard F; Bennis Y; Roubaud S; Gauthier-Villano L; Pisano P; Pourroy B Am J Health Syst Pharm; 2014 Mar; 71(6):476-81. PubMed ID: 24589539 [TBL] [Abstract][Full Text] [Related]
33. An evaluation of chemotherapy drug preparation process in hospitals in Turkey - A pilot study. Bayraktar-Ekincioglu A; Korubük G; Demirkan K J Oncol Pharm Pract; 2018 Dec; 24(8):563-573. PubMed ID: 28728495 [TBL] [Abstract][Full Text] [Related]
34. Telepharmacy and bar-code technology in an i.v. chemotherapy admixture area. O'Neal BC; Worden JC; Couldry RJ Am J Health Syst Pharm; 2009 Jul; 66(13):1211-7. PubMed ID: 19535660 [TBL] [Abstract][Full Text] [Related]
35. Treatment time, ease of use and cost associated with use of Equashield™, PhaSeal Kicenuik K; Northrup N; Dawson A; Locke J; Villamil JA; Chretin J; Sfiligoi G; Clifford C; Rosenberg M; Hamilton T; Regan R; Parsons-Doherty M; Mallett C; Philibert J; Impellizeri J; Hofmeister E Vet Comp Oncol; 2017 Mar; 15(1):163-173. PubMed ID: 25864458 [TBL] [Abstract][Full Text] [Related]
36. The assessment of environmental and external cross-contamination in preparing ready-to-administer cytotoxic drugs: a comparison between a robotic system and conventional manual production. Werumeus Buning A; Geersing TH; Crul M Int J Pharm Pract; 2020 Feb; 28(1):66-74. PubMed ID: 31489970 [TBL] [Abstract][Full Text] [Related]
37. [Evaluation of platinum contamination of a hazardous drug preparation area in a hospital pharmacy]. Leboucher G; Serratrice F; Bertholle V; Thore L; Bost M Bull Cancer; 2002 Nov; 89(11):949-55. PubMed ID: 12495882 [TBL] [Abstract][Full Text] [Related]
38. Impact of closed-system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Miyake T; Iwamoto T; Tanimura M; Okuda M Springerplus; 2013 Dec; 2(1):273. PubMed ID: 23853750 [TBL] [Abstract][Full Text] [Related]
39. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Wick C; Slawson MH; Jorgenson JA; Tyler LS Am J Health Syst Pharm; 2003 Nov; 60(22):2314-20. PubMed ID: 14652980 [TBL] [Abstract][Full Text] [Related]
40. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Yoshida J; Tei G; Mochizuki C; Masu Y; Koda S; Kumagai S Ann Occup Hyg; 2009 Mar; 53(2):153-60. PubMed ID: 19261696 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]